GE Healthcare UK interview (I): Using the early health model to transform healthcare delivery
This article was originally published in Clinica
GE Healthcare has evolved over the last decade from a product-focused company into a provider of a range of diagnostic capabilities to address a disease or condition, frequently in consultation with national healthcare decision-makers. Now on the threshold of another major expansion, bringing divisions of Abbott Laboratories into the fold, and with its strengths in molecular medicine and a combined in vitro and in vivo approach to diagnostics, the group has a unique role to play in the way modern healthcare is delivered, Nigel Mason, president of GE Healthcare UK, told Ashley Yeo
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.